Towards disease modification in osteoarthritis

被引：2
|
作者：
Dell'Accio, Francesco [1 ]
De Bari, Cosimo [2 ]
机构：
[1] Queen Mary Univ London, William Harvey Res Inst, London, England
[2] Univ Aberdeen, Ctr Arthrit & Musculoskeletal Hlth, Aberdeen, Scotland
来源：
OSTEOARTHRITIS AND CARTILAGE | 2023年 / 31卷 / 09期
关键词：
LIPID-METABOLISM; INHIBITION; ANGPTL3;
D O I：
10.1016/j.joca.2023.05.002
中图分类号：
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];
学科分类号：
摘要：
In December 2022, Gerwin et al published in Nature Medicine that the C-terminal portion of angiopoietin-like 3, called LNA043, has chondroprotective and cartilage-regenerative properties. Molecular data from an experimental medicine phase I study suggested potential efficacy in humans. Here, we respond to and complement a commentary from Vincent and Conaghan and discuss unresolved issues and the potential of this molecule as a disease-modifying osteoarthritis drug. (c) 2023 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
引用
收藏
页码：1154 / 1155
页数：2
相关论文
共 50 条
  • [1] Prospects for disease modification in osteoarthritis
    Steven B Abramson
    Mukundan Attur
    Yusuf Yazici
    Nature Clinical Practice Rheumatology, 2006, 2 : 304 - 312
  • [2] Prospects for disease modification in osteoarthritis
    Abramson, Steven B.
    Attur, Mukundan
    Yazici, Yusuf
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2006, 2 (06): : 304 - 312
  • [3] Disease modification in osteoarthritis: are we there yet?
    Oo, W. M.
    Hunter, D. J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (05) : 135 - 140
  • [4] Disease modification in osteoarthritis: Are drugs the answer?
    Dieppe, P
    ARTHRITIS AND RHEUMATISM, 2005, 52 (07): : 1956 - 1959
  • [5] Targeting aging for disease modification in osteoarthritis
    Colins, John A.
    Diekman, Brian O.
    Loeser, Richard F.
    CURRENT OPINION IN RHEUMATOLOGY, 2018, 30 (01) : 101 - 107
  • [6] Opening up a pathway for disease modification in osteoarthritis
    Bradley, Conor A.
    NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (07) : 497 - 497
  • [7] APPA PROVIDES DISEASE MODIFICATION IN PRECLINICAL OSTEOARTHRITIS
    Glasson, S.
    Bendele, A.
    Larkins, N.
    OSTEOARTHRITIS AND CARTILAGE, 2012, 20 : S72 - S73
  • [8] Pharmacologic therapy for osteoarthritis—the era of disease modification
    David J. Hunter
    Nature Reviews Rheumatology, 2011, 7 : 13 - 22
  • [9] Chondrocyte genomics: implications for disease modification in osteoarthritis
    Marshall, K. Wayne
    Zhong, Hongwei
    Nossova, Nadine
    DRUG DISCOVERY TODAY, 2006, 11 (17-18) : 825 - 832
  • [10] APPA provides disease modification in preclinical osteoarthritis
    Glasson, S.
    Bendele, A.
    Larkins, N.
    PLANTA MEDICA, 2012, 78 (11) : 1192 - 1193
12345